We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Charles River Laboratories (CRL - Free Report) will announce quarterly earnings of $2.43 per share in its forthcoming report, representing a decline of 10.7% year over year. Revenues are projected to reach $977.22 million, declining 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Charles River metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Research Models and Services' of $193.20 million. The estimate suggests a change of +3.4% year over year.
Based on the collective assessment of analysts, 'Revenues- Discovery and safety assessment' should arrive at $597.30 million. The estimate points to a change of -10.1% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Manufacturing support' at $188.12 million. The estimate suggests a change of +7% year over year.
According to the collective judgment of analysts, 'Revenues- Services' should come in at $802.67 million. The estimate indicates a change of -7.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Products' will reach $169.97 million. The estimate indicates a year-over-year change of +8.4%.
Analysts' assessment points toward 'Operating income- Research Models and Services Non-GAAP' reaching $46.02 million. The estimate is in contrast to the year-ago figure of $35.29 million.
Analysts expect 'Operating income- Discovery and safety assessment - Non-GAAP' to come in at $143.46 million. Compared to the current estimate, the company reported $180.52 million in the same quarter of the previous year.
Analysts predict that the 'Operating income- Manufacturing support - Non-GAAP' will reach $49.98 million. Compared to the present estimate, the company reported $43.03 million in the same quarter last year.
Shares of Charles River have experienced a change of -5.1% in the past month compared to the +0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), CRL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Charles River Laboratories (CRL - Free Report) will announce quarterly earnings of $2.43 per share in its forthcoming report, representing a decline of 10.7% year over year. Revenues are projected to reach $977.22 million, declining 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Charles River metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Research Models and Services' of $193.20 million. The estimate suggests a change of +3.4% year over year.
Based on the collective assessment of analysts, 'Revenues- Discovery and safety assessment' should arrive at $597.30 million. The estimate points to a change of -10.1% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Manufacturing support' at $188.12 million. The estimate suggests a change of +7% year over year.
According to the collective judgment of analysts, 'Revenues- Services' should come in at $802.67 million. The estimate indicates a change of -7.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Products' will reach $169.97 million. The estimate indicates a year-over-year change of +8.4%.
Analysts' assessment points toward 'Operating income- Research Models and Services Non-GAAP' reaching $46.02 million. The estimate is in contrast to the year-ago figure of $35.29 million.
Analysts expect 'Operating income- Discovery and safety assessment - Non-GAAP' to come in at $143.46 million. Compared to the current estimate, the company reported $180.52 million in the same quarter of the previous year.
Analysts predict that the 'Operating income- Manufacturing support - Non-GAAP' will reach $49.98 million. Compared to the present estimate, the company reported $43.03 million in the same quarter last year.
View all Key Company Metrics for Charles River here>>>
Shares of Charles River have experienced a change of -5.1% in the past month compared to the +0.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), CRL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>